The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments.
Researchers plan to sequence 5,000 genomes and collect health and fitness data to tease out the role of genetics in things like aerobic capacity and bone density.
Natera said that this research collaboration and others will help it clinically validate its circulating tumor DNA assay Signatera.
Curetis and BGI subsidiary MGI Tech plan to develop NGS-based diagnostics for microbial infections on the MGISeq instrument for the Chinese market.
PacBio is refining the CRISPR/Cas9 capture technique with several early- access sites and plans to launch it more broadly in 2018.
Next year, the company will submit regulatory filings for the drug in two molecularly defined indications and a next-generation sequencing companion diagnostic.
Last week, the company launched whole-genome sequencing of children for customers of its ViaCord cord blood and tissue banking business.
The firms will use MGI's sequencing technology and Curetis' sample prep platform and antibiotic resistance database to develop IVDs, initially for China.
The nanopore ZMW can enable lower starting amounts of DNA for PacBio sequencing, and may eventually enable direct RNA sequencing.
The company's Hong Kong laboratory was established in 2010 and was accredited by the College of American Pathologists in 2013.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.